Atara Biotherapeutics

Historical price data

Atara Biotherapeutics is focused on unleashing the power of the body's immune system by developing next-generation, allogeneic T-cell immunotherapies. Its core technology utilizes donor-derived EBV T cells, which do not require T-cell receptor or HLA gene editing, enabling the creation of scalable, off-the-shelf treatments. The company has achieved the landmark approval of EBVALLO™ for post-transplant lymphoproliferative disease and is advancing a pipeline of next-generation CAR T candidates for B-cell cancers and autoimmune diseases. Atara's strategy centers on overcoming the limitations of current autologous cell therapies through rapid delivery and scalable manufacturing.

Proprietary allogeneic Epstein-Barr Virus (EBV) T-cell platform that utilizes donor-derived T cells with known EBV specificity, requiring no TCR or HLA gene editing, serving as a foundation for off-the-shelf virus-specific and CAR T immunotherapies.

Atara competes with allogeneic cell therapy firms like Allogene Therapeutics and CRISPR Therapeutics, differentiating through its non-gene-edited EBV T-cell platform aimed at preserving T-cell fitness. It also faces future competition in autoimmune CAR T from companies like Kyverna Therapeutics, where its off-the-shelf model could provide an access advantage.